The protein Kinase C inhibitor: Ruboxistaurin

Developments in Ophthalmology

Volumn 55, Issue , 2015, Pages 295-301

  Deissler, Heidrun L ^a   Lang, Gabriele E ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; INDOLE DERIVATIVE; MALEIMIDE DERIVATIVE; PROTEIN KINASE C; RUBOXISTAURIN;

ANTAGONISTS AND INHIBITORS; DIABETIC RETINOPATHY; HUMAN;

DIABETIC RETINOPATHY; ENZYME INHIBITORS; HUMANS; INDOLES; MALEIMIDES; PROTEIN KINASE C;

EID: 84947227107     PISSN: 02503751     EISSN: 16622790     Source Type: Book Series    
DOI: 10.1159/000431204     Document Type: Article

References (46)

1. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331:1480-1487.
2. Caldwell RB, Bartoli M, Behzadian MA, et al. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 2003; 19:442-455.
3. Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006; 142:961-969.
4. Way KJ, Katai N, King GL: Protein kinase C and the development of diabetic vascular complications. Diabet Med 2001; 18:945-959.
5. Aiello LP: The potential role of PKC β in diabetic retinopathy and macular edema. Surv Ophthalmol 2002; 47(suppl 2):S263-S269.
6. Clarke M, Dodson PM: PKC inhibition and diabetic microvascular complications. Best Pract Res Clin Endocrinol Metab 2007; 21:573-586.
7. Evicmen ND, King GL: The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res 2007; 55:498-510.
8. Lang GE, Kampmeier J: Die Bedeutung der Proteinkinase C in der Pathophysiologie der diabetischen Retinopathie. Klin Monatsbl Augenheilkd 2002; 219:769-776.
9. Suzuma K, Takahara N, Suzuma I, et al. Characterization of protein kinase C β isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced cell proliferation, and retinal neovascularization. Proc Natl Acad Sci U S A 2002; 99:721-726.
10. Idris I, Donelly R: Protein kinase Cβ inhibition: a novel therapeutic strategy for diabetic microangiopathy. Diab Vasc Dis Res 2006; 3:172-178.
11. Meier M, King GL: Protein kinase C activation and its pharmacological inhibition in vascular disease. Vasc Med 2000; 5:173-185.
12. Taulien CA, Joy SV: Ruboxistaurin. Drugs Today (Barc) 2006; 42:577-585.
13. Rask-Madsen C, King GL: Differential regulation of VEGF signaling by PKCα and PKCε in endothelial cells. Arterioscler Thromb Vasc Biol 2008; 28:919-924.
14. Xia P, Aiello LP, Ishii H, et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 1996; 98:2018-2026.
15. Craven PA, Davidson CM, DeRubertis FR: Increase in diacylglycerol mass in isolated glomeruli by glucose from de novo synthesis of glycerolipids. Diabetes 1990; 39:667-674.
16. Kishimoto A, Takai Y, Mori T, et al. Activation of calcium and phospholipid-dependent protein kinase by diacylglycerol, its possible relation to phosphatidylinositol turnover. J Biol Chem 1980; 255:2273-2276.
17. Xia P, Inoguchi T, Kern TS, et al. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes 1994; 43:1122-1129.
18. Crider JY, Yorio T, Sharif NA, et al. The effects of elevated glucose on Na+/K+-ATPase of cultured bovine retinal pigment epithelial cells measured by a new nonradioactive rubidium uptake assay. J Ocul Pharmacol Ther 1997; 13:337-352.
19. Hempel A, Maasch C, Heintze U, et al. High glucose concentrations increase endothelial cell permeability via activation of protein kinase Cα . Circ Res 1997; 81:363-371.
20. Amadio M, Osera C, Lupo G, et al. Protein kinase C activation affects, via the mRNA-binding Hu-Antigen R/ELAV protein, vascular endothelial growth factor expression in a pericytic/endothelial coculture model. Mol Vis 2012; 18:2153-2164.
21. Amadio M, Scapagnini G, Lupo G, et al. PKCβ II/HuR/VEGF: a new molecular cascade in retinal pericytes for the regulation of VEGF gene expression. Pharmacol Res 2008; 57:60-66.
22. Harhaj NS, Felinski EA, Wolpert EB, et al. VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability. Invest Ophthalmol Vis Sci 2006; 47:5106-5115.
23. Deissler H, Deissler H, Lang GE: Inhibition of protein kinase C is not sufficient to prevent or reverse effects of VEGF165 on claudin-1 and permeability in microvascular endothelial cells. Invest Ophthalmol Vis Sci 2010; 51:535-542.
24. Bazzoni G: Endothelial tight junctions: permeable barriers of the vessel wall. Thromb Haemost 2006; 95:36-42.
25. Deissler H, Deissler H, Lang S, Lang GE: VEGF-induced effects on proliferation, migration and tight junctions are restored by ranibizumab (Lucentis® ) in microvascular retinal endothelial cells. Br J Ophthalmol 2008; 92:839-843.
26. Lopez-Quintero SV, Ji XY, Antonetti DA, et al. A three-pore model describes transport properties of bovine retinal endothelial cells in normal and elevated glucose. Invest Ophthalmol Vis Sci 2011; 52:1171-1180.
27. Park JY, Takahara N, Gabariele A, et al. Induction of endothelin-1 expression by glucose. Diabetes 2000; 49:1239-1248.
28. Yokota T, Ma RC, Park JY, et al. Role of protein kinase C on the expression of platelet-derived growth factor and endothelin-1 in the retina of diabetic rats and cultured retinal capillary pericytes. Diabetes 2003; 52:838-845.
29. Campochiaro PA; C99-PKC412-003 Study Group: Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest Ophthalmol Vis Sci 2004; 45:922-931.
30. Ishii H, Jirousek MR, Koya D, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC-β inhibitor. Science 1996; 272:728-731.
31. Jirousek MR, Gillig JR, Gonzalez CM, et al. (S)-13-[(dimethylamino)methyl]-10, 11, 14, 15-Detrahydro-4, 9:16, 21-dimetheno-1H, 13H-dibenzo[e, k]pyrrolo[3, 4-h][1, 4, 13]oxadiazacyclohexadecene-1, 3(2H)-dione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase Cβ . J Med Chem 1996; 39:2664-2671.
32. Ring BJ, Gillespie JS, Binkley SN, et al. The interactions of a selective protein kinase β inhibitor with the human cytochromes P450. Drug Metab Dispos 2002; 30:957-961.
33. Burkey JL, Campanale KM, Barbuch R, et al. Disposition of [14C]ruboxistaurin in humans. Drug Metab Dispos 2006; 34:1909-1917.
34. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997; 46:1473-1480.
35. Koya D, Haneda M, Nakagawa H, et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC β inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 2000; 14:439-447.
36. Danis RP, Bingaman DP, Jirousek M, et al. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCβ inhibition with LY333531. Invest Ophthalmol Vis Sci 1998; 39:171-179.
37. Casselini CM, Barlow PM, Rice AL, et al. A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase Cβ inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy. Diabetes Care 2007; 30:896-902.
38. Vinik AI, Bril V, Kempler P, et al. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C β-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial. Clin Ther 2005; 27:1164-1180.
39. Tuttle KR, Bakris GL, Tot RD, et al. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 2005; 28:2686-2690.
40. Strom C, Sander B, Klemp K, et al. Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema. Invest Ophthalmol Vis Sci 2005; 46:3855-3858.
41. Aiello LP, Clermont A, Arora V, et al. Inhibition of PKCβ by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest Ophthalmol Vis Sci 2006; 47:86-92.
42. PKC-DRS Study Group: The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C β Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes 2005; 54:2188-2197.
43. PKC-DMES Study Group: Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial. Arch Ophthalmol 2007; 125:318-324.
44. PKC-DRS2 Group, Aiello LP, Davis MD, et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 2006; 113:2221-2230.
45. Sheetz MJ, Aielleo LP, Shahri N, Davis MD, Kles KA, Danis RP; Mbdv Study Group: Effect of ruboxistaurin (RBX) on visual acuity decline over a 6-year period with cessation and reinstititution of therapy: results of an open-label extension of the Protein Kinase C Diabetic Retinopathy Study 2 (PKC-DRS2). Retina 2011; 31:1053-1059.
46. Yeo KP, Lowe SL, Lim MT, et al. Pharmacokinetics of ruboxistaurin are significantly altered by rifampicin-mediated CYP3A4 induction. Br J Clin Pharmacol 2005; 61:200-210.